Study: GSK Avandia prevents Type 2 diabetes

09/16/2006 | Forbes

A European study says GlaxoSmithKline's Avandia reduced by 62% the number of people with high blood sugar who developed Type 2 diabetes. The study in the journal Lancet also said the drug had significant side effects, and some experts are calling attention to the increased risk for heart problems.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA